Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease☆
References (23)
- et al.
Clinical relevance of the quantification of Apo E in cerebrospinal fluid
Clin. Chim. Acta
(1991) - et al.
Lipoproteins and their receptor in the central nervous system: characterization of the lipoproteins in the cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain
J. Biol. Chem.
(1987) Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease
Trends Neurosci.
(1994)- et al.
Cerebrospinal fluid Apoliprotein E is reduced in Alzheimer's disease
NeuroReport
(1994) - et al.
Apolipoprotein E associated with astrocytic glia of the nervous system and with nonmyelinating glia of the peripheral nervous system
J. Clin. Invest.
(1985) - et al.
Confirmation of the ϵ4 allel of the apolipoprotein E gene as a risk factor for late-onset Alzheimer's disease
Neurology
(1994) - et al.
Apo E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets
- et al.
An enzyme-linked immunosorbent assay method to measure human apolipoprotein E levels using commercially available reagents: effect of apolipoprotein E polymorphism on serum apolipoprotein E concentration
Anal. Biochem.
(1994) - et al.
Cerebral blood flow in dementia
Arch. Neurol.
(1975) Development of a rating scale for primary depression illness
Br. J. Soc. Clin. Psychol.
(1967)
Apolipoproteint E (Apo E) polymorphism and its influence on Apo E concentration in the cerebrospinal fluid in Finnish patients with Alzheimer's disease
Hum. Genet.
Cited by (44)
Meta-analysis of apolipoprotein e levels in the cerebrospinal fluid of patients with Alzheimer's disease
2016, Journal of the Neurological SciencesAn ultrasensitive electrochemical immunosensor for apolipoprotein E4 based on fractal nanostructures and enzyme amplification
2015, Biosensors and BioelectronicsCitation Excerpt :The detection limit for human APOE4 based on the FracAu electrochemical immunosensor is 0.3 ng/mL (S/N=3, Fig. 4C red line). In physiological conditions, the concentration of APOE4 is typically in the μg/mL range for cerebrospinal fluid (CSF) in the individuals that do have APOE4 allele (Lefranc et al., 1996). Hence, the detection limit of the as-fabricated electrochemical immunosensor can meet the requirements of clinical application.
Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n = 669): A pilot assay for methionine-containing proteotypic peptides
2012, Molecular and Cellular ProteomicsCitation Excerpt :The same influencing order is found for brain amyloid β accumulation across cognitively normal individuals as demonstrated by imaging studies (82–85). Thus, a large body of evidence converges on a pivotal role of ApoE in the neurodegeneration process associated with a possible disruption of ApoE levels in the cerebrospinal fluid (7, 86–95). This is reinforced by the recent article by Cramer et al. who demonstrated reduced Aβ plaque area and improved cognitive functions in a mouse model of AD after treatment by bexarotene, an agonist of nuclear receptors that transcriptionally regulates ApoE expression (96).
Cerebrospinal fluid apolipoprotein e levels in subacute sclerosing panencephalitis
2012, Brain and DevelopmentCitation Excerpt :Experimental studies have shown that Apo E influences the majority of the pathological processes of AD, including amyloid-beta (Ab) deposition and tangle formation [6]. Although ApoE takes part in the pathogenesis of AD disease, cerebrospinal fluid Apo E levels are not significantly changed in AD compared to control subjects [7,8]. Apo E may be involved in the pathogenesis of subacute sclerosing panencephalitis (SSPE), a persistent infection of the central nervous system (CNS) characterized by a subacute inflammatory process and degenerative changes including perivascular lymphocytic infiltrates, neuronal loss, demyelinization, and neuronal inclusion bodies [9].
Association of ApoE and LRP mRNA levels with dementia and AD neuropathology
2012, Neurobiology of AgingQuantitative proteomics and metabolomics analysis of normal human cerebrospinal fluid samples
2010, Molecular and Cellular ProteomicsCitation Excerpt :Here we examined well-defined CSF samples obtained from patients who did not have neurological disorders and we found profound differences in protein abundances between individuals. Characterization of variation of CSF levels of amyloid beta (33) and apolipoprotein E (34) in patients who have Alzheimer's disease have been published, but this is the first attempt to characterize a large number of proteins in CSF of patients who do not have neurological afflictions. Some proteins, such as serotransferrin and fibulin-1, appear to be more constant than others with regards to abundance levels in CSF, as these showed only limited variations in both the sample set of nine non-neurological individuals and the validation set as well as in the experimental sample set.
- ☆
This work was supported by a grant from the Conseil Régional du Nord-Pas-de-Calais and the CHR&U of Lille.